This study is being done to evaluate the safety and pharmacokinetic profile of MK-8242 and
its active metabolite (M16) in participants with advanced solid tumors. In Part 1 of the
study, the study drug dose will be escalated to determine the maximum tolerated dose (MTD).
In Part 2 of the study, the MTD will be confirmed and the recommended Phase 2 dose (RPTD)
established; the effect of MK-8242 on liposarcoma and other tumor types will also be